Scilex Holding (SCLXW) Total Debt (2021 - 2026)
Scilex Holding (SCLXW) recorded quarterly Total Debt of $80.8 million in Q1 2026, down 23.6% quarter-over-quarter from $105.7 million in Q4 2025, and up 104.81% on a YoY basis from $39.4 million in Q1 2025.
Scilex Holding (SCLXW) Total Debt (2021 - 2026) Analysis & Trends
Scilex Holding's Total Debt history runs 6 years deep, the most recent figure standing at $80.8 million for Q1 2026.
- In Q1 2026, Total Debt rose 104.81% year-over-year to $80.8 million; the TTM figure through Mar 2026 stood at $80.8 million (up 104.81% YoY), while the FY2025 annual figure was $105.7 million, up 196.02% from the prior year.
- Total Debt was $80.8 million for Q1 2026 at Scilex Holding, down from $105.7 million in the prior quarter.
- In the past five years, Total Debt ranged from a high of $125.5 million in Q4 2023 to a low of $2.0 million in Q2 2022.
- Historically, Total Debt has averaged $66.3 million across 5 years, with a median of $63.2 million in 2025.
- The sharpest annual moves came in 2023 and 2024: Total Debt jumped 4010.62% in 2023, then slumped 71.53% in 2024.
- A 5-year view of Total Debt shows it stood at $3.0 million in 2022, then soared by 4122.11% to $125.5 million in 2023, then sank by 71.53% to $35.7 million in 2024, then surged by 196.02% to $105.7 million in 2025, then decreased by 23.6% to $80.8 million in 2026.
- The last three Total Debt figures came in at $80.8 million (Q1 2026), $105.7 million (Q4 2025), and $45.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -18.89 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 43.37 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 54.99 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 64.53 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 49.12 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 57.32 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 22.17 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 64.46 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 44.46 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn | 80.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 80.78 Mn |
| Dec 31, 2025 | 105.74 Mn |
| Sep 30, 2025 | 45.67 Mn |
| Jun 30, 2025 | 39.87 Mn |
| Mar 31, 2025 | 39.44 Mn |
| Dec 31, 2024 | 35.72 Mn |
| Sep 30, 2024 | 98.97 Mn |
| Jun 30, 2024 | 104.40 Mn |
| Mar 31, 2024 | 109.25 Mn |
| Dec 31, 2023 | 125.47 Mn |
| Sep 30, 2023 | 122.15 Mn |
| Jun 30, 2023 | 15.92 Mn |
| Sep 30, 2022 | 2.97 Mn |
| Jun 30, 2022 | 2.00 Mn |
| Dec 31, 2021 | 109.99 Mn |